Peptides DB
Research-centric peptide and protocol reference hub

TB-500 (Thymosin Beta-4 Fragment) record · updated 18h ago

Healing & recoveryMuscle & body compGrade B · human evidenceResearch use only
All 9 studiesJump to the evidenceCompare
What is TB-500 (Thymosin Beta-4 Fragment) used for?

TB-500, a synthetic derivative of thymosin beta-4, is a peptide that has garnered attention for its potential role in tissue repair and regeneration. Research into TB-500 is ongoing, particularly regarding its applications in equine medicine and its implications in doping control.

How it works: Actin-sequestering peptide; promotes cell migration & angiogenesis

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection (research use)

Development stage

where TB-500 (Thymosin Beta-4 Fragment) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 13 registered trials. It describes the research record, not a recommendation.

Identity
NameTB-500 (Thymosin Beta-4 Fragment)
Chain length7 amino acids
Molecular weight889 Da
FormulaC38H68N10O14
Structure typePeptide
ClassHealing
Research levelPreclinical
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 62707662. The chain length is only shown where the residues account for that mass, so a figure here has been checked against it rather than taken on trust.

Pharmacology
MechanismActin-sequestering peptide; promotes cell migration & angiogenesis
RouteSubcutaneous injection (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies9
Human / animal / cellular2 / 3 / 1
Highest trial phasePreclinical
Years covered2011–2026
Latest study28d ago
Publication history
20112026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

9 rowsOpen in the library →
StudyTypeYearSummary depth
De novo cardiomyocytes from within the activated adult heart after injury.
TakeawayNot reported in abstract.
—2011Title only0.10
In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes.
TakeawayNot reported in abstract.
Animal2012Title only0.10
JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy.
FindingNot reported in abstract.
Animal2026Full text read0.70
OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.
FindingNot reported in abstract.
Human2026Full text read0.70
Construction and validation of a prediction model for graft failure in pediatric liver transplant recipients based on the APRI-ALBI score: a retrospective study of 289 cases.
FindingAUC of 0.706 for the nomogram predicting graft failure.
Human2026Full text read0.80
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
FindingNot reported in abstract.
review2026Full text read0.70
Semantic Scholar search for TB-500 (Thymosin Beta-4)
TakeawayNot reported in abstract.
—2026Title only0.00
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
FindingNot reported in abstract.
In vitro2012Partial text0.50
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
FindingN-acetylated LKKTETQ detected at 0.02 ng/mL in equine plasma.
Animal2012Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching TB-500 (Thymosin Beta-4 Fragment) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much TB-500 (Thymosin Beta-4 Fragment) is discussed should be drawn from it.

Articles mentioning TB-500 (Thymosin Beta-4 Fragment)